Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) to Post Q2 2022 Earnings of ($0.67) Per Share, Oppenheimer Forecasts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARSGet Rating) – Research analysts at Oppenheimer boosted their Q2 2022 earnings per share estimates for shares of Tarsus Pharmaceuticals in a research report issued to clients and investors on Monday, May 2nd. Oppenheimer analyst F. Brisebois now expects that the company will post earnings per share of ($0.67) for the quarter, up from their prior estimate of ($0.71). Oppenheimer also issued estimates for Tarsus Pharmaceuticals’ Q3 2022 earnings at ($1.11) EPS, Q4 2022 earnings at ($0.78) EPS and FY2022 earnings at ($3.21) EPS.

Several other equities research analysts have also recently issued reports on the company. Zacks Investment Research upgraded Tarsus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, February 24th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Tarsus Pharmaceuticals in a research note on Tuesday. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Tarsus Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $48.00.

Shares of NASDAQ:TARS opened at $12.92 on Thursday. The stock has a market cap of $267.56 million, a PE ratio of -17.94 and a beta of 1.44. The business has a 50 day moving average of $17.81 and a 200-day moving average of $21.17. Tarsus Pharmaceuticals has a 12-month low of $12.25 and a 12-month high of $39.08.

Tarsus Pharmaceuticals (NASDAQ:TARSGet Rating) last issued its quarterly earnings data on Monday, March 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 7.66% and a negative net margin of 24.25%. The company had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $7.11 million.

Several large investors have recently made changes to their positions in the company. Citigroup Inc. increased its holdings in shares of Tarsus Pharmaceuticals by 123.0% during the fourth quarter. Citigroup Inc. now owns 2,145 shares of the company’s stock worth $48,000 after buying an additional 1,183 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Tarsus Pharmaceuticals by 6.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 28,103 shares of the company’s stock worth $632,000 after buying an additional 1,623 shares in the last quarter. Geode Capital Management LLC increased its holdings in Tarsus Pharmaceuticals by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 125,815 shares of the company’s stock valued at $2,830,000 after purchasing an additional 2,117 shares during the period. State Street Corp increased its holdings in Tarsus Pharmaceuticals by 2.3% in the fourth quarter. State Street Corp now owns 129,742 shares of the company’s stock valued at $2,919,000 after purchasing an additional 2,940 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in Tarsus Pharmaceuticals by 13.7% in the third quarter. Bank of New York Mellon Corp now owns 24,523 shares of the company’s stock valued at $529,000 after purchasing an additional 2,950 shares during the period. Institutional investors own 70.00% of the company’s stock.

In other Tarsus Pharmaceuticals news, major shareholder Vivo Capital Ix, Llc sold 19,738 shares of the company’s stock in a transaction on Wednesday, May 4th. The stock was sold at an average price of $12.67, for a total transaction of $250,080.46. Following the completion of the sale, the insider now directly owns 2,474,375 shares in the company, valued at $31,350,331.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 33.08% of the stock is owned by corporate insiders.

About Tarsus Pharmaceuticals (Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

See Also

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.